Your search returned 40 studies. (Get alerts for new studies):
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL - Lymphoma, Non-Hodgkin - Lymphoma, B-Cell - Lymphoma, Follicular - Lymphoma, Intermediate-Grade - Lymphoma, Large-Cell - Lymphoma, Low-Grade - Lymphoma, Mixed-Cell - Lymphoma, Small-Cell - Leukemia, Lymphocytic, Chronic - Leukemia, B-Cell, Chronic -
4 Locations available
- Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Conditions: Lymphoma, Follicular
14 Locations available
- Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Conditions: Lymphoma, Follicular
4 Locations available
- Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma
3 Locations available
- Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Adult Diffuse Mixed Cell Lymphoma - Recurrent Adult Diffuse Small Cleaved Cell Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine
Conditions: Diffuse Large B-Cell Lymphoma - Transformed Follicular Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
1 Location available
- Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
Conditions: Non-Hodgkin's Lymphoma
1 Location available
- A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Conditions: Lymphoma, B-Cell - Follicular Lymphoma
1 Location available
- Evaluate Rituximab in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Conditions: Non-Hodgkins Lymphoma
2 Locations available
- Autologous Vaccine for Follicular Lymphoma
Conditions: Lymphoma, Follicular
3 Locations available
- Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: Indolent Non-Hodgkin Lymphoma - Follicular Lymphoma - Small Lymphocytic Lymphoma - Lymphoplasmacytoid Lymphoma - Marginal Zone Lymphoma
24 Locations available
- Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent Grade 3 Follicular Lymphoma - Recurrent Mantle Cell Lymphoma
1 Location available
- Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma - Contiguous Stage II Adult Diffuse Large Cell Lymphoma - Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma - Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma - Contiguous Stage II Grade 1 Follicular Lymphom
1 Location available
- Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Conditions: Lymphoma
20 Locations available
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue - Nodal Marginal Zone B-cell Lymphoma - Recurrent Adult Diffuse Large Cell Lymphoma - Recurrent Grade 1 Follicular Lymphoma - Recurrent Grade 2 Follicular Lymphoma - Recurrent G
1 Location available
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Conditions: Lymphoma
79 Locations available
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Lymphoma
4 Locations available
- Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- Oral Clofarabine for Relapsed/Refractory Indolent B-cell NHL and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma - Mantle Cell Lymphoma - Small Lymphocytic Lymphoma - Lymphoplasmacytic Lymphoma - Low Grade B-cell Lymphoma, Not Otherwise Specified
2 Locations available
- Lenalidomide and Rituximab in Treating Patients With Follicular or Small Lymphocytic Non-Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatm
Conditions: Lymphoma
1 Location available
- A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin - Lymphoma - Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell - Lymphomas: Non-Hodgkin
1 Location available
- Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701
Conditions: Lymphoma, Non-Hodgkin
34 Locations available
- Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma - Small Lymphocytic Lymphoma
2 Locations available
- Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lympho
Conditions: Diffuse Large B-cell Lymphoma - de Novo DLBCL - DLBCL Transformed From Indolent Lymphoma - Follicular Grade 3 Lymphoma
123 Locations available
- Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia - Follicular Lymphoma - Chronic Lymphocytic Leukemia (CLL) - Mantle Cell Lymphoma - Prolymphocytic Leukemia - Large Cell Lymphoma
1 Location available
- Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to
Conditions: Lymphoma, Non-Hodgkin - Lymphoma, Follicular
6 Locations available
- A Phase 1-2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia (CLL) - Diffuse Large B-Cell Lymphoma (DLBCL) - Non-Hodgkin's Lymphoma (NHL) - Follicular Lymphoma (FL) - Mantle Cell Lymphoma (MCL)
1 Location available
- First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leuke
Conditions: Acute Myelogenous Leukemia - Diffuse Large B-Cell Leukemia - Chronic Lymphocytic Leukemia - Follicular Lymphoma
6 Locations available
- Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Follicular Lymphoma - Marginal Zone Lymphoma
1 Location available
- Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin
11 Locations available
- Imexon for Relapsed Follicular and Aggressive Lymphomas
Conditions: Follicular Lymphoma - Diffuse Large B Cell Lymphoma - Mantle Cell Lymphoma - Burkitt's Lymphoma
1 Location available
- Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prio
Conditions: Chronic Lymphocytic Leukemia - Small Lymphocytic Lymphoma - Mantle Cell Lymphoma - Follicular Lymphoma - Large Cell Lymphoma
1 Location available
- GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Conditions: Lymphoma
1 Location available
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom
Conditions: Lymphoma
2 Locations available
- Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
Conditions: Follicular Lymphoma
1 Location available
- Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Conditions: Lymphoma
50 Locations available
- Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Conditions: Follicular Lymphoma
21 Locations available
- Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Ly
Conditions: Non-Hodgkin's Lymphoma
1 Location available
|